Abstract: The present invention is directed to an iron-promoted zeolite beta catalyst useful in the selective catalytic reduction of nitrogen oxides with ammonia in which the iron-promoted zeolite beta is treated so as to provide increased amounts of the iron promoter in the form of Fe(OH). The stabilized zeolite is formed by cation exchange of an iron salt into a zeolite beta which has a reduced sodium content such as by exchanging a sodium beta with ammonium or hydrogen cations. A zeolite beta having a reduced carbon content and a Si/Al ratio of no more than 10 also increases the Fe(OH) content of the iron-promoted catalyst. The iron-promoted catalyst which has the iron in the form of Fe(OH) is characterized by a peak at 3680±5 cm?1 in the IR spectra.

Abstract: Compounds of the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Abstract: Compounds of the formula: 1

Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Abstract: Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

Abstract: Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

Abstract: Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Abstract: The present invention is directed to a metal-promoted zeolite beta catalyst useful in the selective catalytic reduction of nitrogen oxides with ammonia in which the zeolite beta is pre-treated so as to provide the zeolite with improved hydrothermal stability.

Abstract: Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

Abstract: Compounds of the formula: useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.

Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Abstract: Compounds of the formula: 1

Abstract: The present invention is directed to a metal-promoted zeolite beta catalyst useful in the selective catalytic reduction of nitrogen oxides with ammonia in which the zeolite beta is pre-treated so as to provide the zeolite with improved hydrothermal stability. The stabilized beta zeolite is provided by incorporating into the zeolite structure non-framework aluminum oxide chains. The aluminum oxide chains can be incorporated into the zeolite structure by a unique steaming regimen or by treatment with rare earth metals, such as cerium. The treatment process is unlike well-known methods of dealuminizing zeolites for the purpose of increasing the silica to alumina ratio. In the present invention, the non-framework aluminum oxide is characterized by FT-IR by a peak at 3781±2 cm−1, which when present, stabilizes the zeolite against further dealumination such as under oxidizing and harsh hydrothermal conditions.

Abstract: The present invention is directed to a metal-promoted zeolite beta catalyst useful in the selective catalytic reduction of nitrogen oxides with ammonia in which the zeolite beta is pre-treated so as to provide the zeolite with improved hydrothermal stability.

Abstract: The present invention is directed to an iron-promoted zeolite beta catalyst useful in the selective catalytic reduction of nitrogen oxides with ammonia in which the iron-promoted zeolite beta is treated so as to provide increased amounts of the iron promoter in the form of Fe(OH).

Abstract: Compounds of the formula: 1

Abstract: Compounds of the formula: 1

Abstract: Compounds of the formula 1

Abstract: A gas stream containing nitrous oxide and ammonia is contacted with a catalyst composition containing a zeolite. N2O is reduced to N2 and H2O at low temperatures in a highly efficient manner. Ammonia-mediated reduction of nitrous oxide can be effectuated from gas streams having N2O concentrations as low as 1%. The gas stream may also contact a catalytic composition selective for the reduction of NOx. In this way, N2O and Nx treatment may be effectuated in a single process stream.

Abstract: The present invention relates to acetylenic aryl sulfonamide thiols which act as inhibitors of TNF-&agr; converting enzyme (TACE). The compounds of the present invention are useful in disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.